Please refer the enclosed intimation letter
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare's Board meeting on May 7, 2026 resulted in multiple outcomes. The Board recommended a final dividend of Rs. 7 per share for FY2025-26, bringing the total dividend to Rs. 9.33 per share (post-bonus). M/s. Price Waterhouse Chartered Accountants LLP was appointed as the new statutory auditor for a 5-year term, replacing M S K A & Associates LLP whose term concluded. Two Non-Executive, Non-Independent Directors — Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah — resigned on the same day, citing preoccupation and other commitments, with no material reasons stated. They were replaced by Mr. Uday Patel Kadam and Mr. Gaurav Verma as Additional Directors (both from API Holdings, the holding company). The Board also approved investing up to Rs. 5.5 crore in Think Health Diagnostics Private Limited (a wholly-owned subsidiary with negligible FY26 turnover) and altering the Memorandum of Association to align with the Companies Act, 2013 and broaden the objects clause to include wider healthcare and diagnostics activities. Mr. Rahul Franklin Guha was re-appointed as Chairman, MD & CEO for five years from May 2027.
The simultaneous resignation of two non-independent directors and their replacement with two API Holdings nominees represents a consolidation of promoter-group control on the board. Investors should note this structural shift, though the stated reasons for resignation do not indicate governance concerns. The dividend and auditor change are routine.